Saisei Ventures Launches Bridge-to-Biotech Venture Creation Initiative

Audio By Carbonatix

TOKYO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb 9, 2026--

Saisei Ventures, a pioneering investment firm focused on advancing Japanese biotechnology and therapeutic innovations globally, today announced the launch of Bridge-to-Biotech, a new initiative designed to support Japanese founders and entrepreneurs as they translate groundbreaking scientific discoveries into venture-ready biotechnology companies.

Bridge-to-Biotech reflects Saisei’s commitment to company creation from the earliest stages of innovation, when clarity of direction and early execution play a meaningful role in shaping long-term outcomes. The program is designed initially for academic scientists and founders who are beginning the company formation process and seeking structured guidance and support as they shape their scientific and commercial vision.

By initiating working with founders in the discovery stage, Bridge-to-Biotech engages entrepreneurs at a key inflection point, when fundamental decisions about development strategy and operations are being made. As a venture creation program, Bridge-to-Biotech supports specific ideas independent of an investment outcome. The program provides hands-on guidance across key early milestones, including the design of proof-of-concept experiments, development of IND-track plans, and early company-building strategy. Founders will meet with experienced biotech and pharma mentors to assist in developing pitch materials, equipping them with everything they will need to effectively communicate their vision to investors and partners.

“Japan has extraordinary discovery science, but the support needed to build companies often arrives too late or not at all. With the support of Japan’s Ministry of Health, Labour and Welfare, we created Bridge-to-Biotech to engage founders early and surround them with global experts and development partners from day one,” said Jonathan Yeh, Managing Partner at Saisei Ventures. “At its core, this program is about supporting the next generation of biotech founders, and helping promising ideas grow into companies that can have global patient impact.”

Learn more at bridgetobiotech.com.

About Saisei Ventures
Saisei Ventures is a life science venture capital firm dedicated to building next-generation companies in the healthcare sector. We create ventures that start from bold ideas and empower dynamic entrepreneurs by providing technical, operational, and financial guidance. Our approach combines Western expertise and Japanese innovations to build globally competitive companies that will have the greatest impact on patient lives. With operations in Japan and the United States, Saisei aims to enhance the value of its portfolio by leveraging its unique networks and the institutional advantages of both countries. For more information, visit saiseiventures.com.

View source version on businesswire.com:https://www.businesswire.com/news/home/20260209959182/en/

CONTACT: Kelli Berg

[email protected]

KEYWORD: UNITED STATES JAPAN NORTH AMERICA ASIA PACIFIC MASSACHUSETTS

INDUSTRY KEYWORD: BIOTECHNOLOGY FINANCE CONSULTING HEALTH PROFESSIONAL SERVICES

SOURCE: Saisei Ventures

Copyright Business Wire 2026.

PUB: 02/09/2026 08:00 AM/DISC: 02/09/2026 08:00 AM

http://www.businesswire.com/news/home/20260209959182/en